Kymera Investor Day Presentation Deck
Skin KT-474 Concentration (ng/g)
Mean (± SD)
400
Once Daily Dosing (14 Days) Resulted in High Skin Exposures
Exceeding Plasma
300-
200
100
●
●
KT-474 Levels in Skin
7
14
Day
25 mg QD
50 mg QD
Ctrough concentrations shown for Days 1, 7 and 14.
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
100 mg QD
A 200 mg QD
T
28
Increasing exposures through Day 14
Ctrough levels in skin ~10-14 fold higher than plasma
on Day 14
Substantially Larger Skin vs Plasma Exposures at Ctrough
[ng/mL for Plasma, ng/g for Skin]
Mean (± SD) Concentration
150-
100
50
ng/mL (plasma)
ng/g (skin)
Plasma Day 7
Plasma Day 14
Skin Day 7
Skin Day 14
Plasma Day 7
Plasma Day 14
Skin Day 7
Skin Day 14
KYMERA R&D DAY - December 16th, 2021
25 mg QD
(n=9)
3.21
4.72
21.5
44.5
50 mg QD
(n=9)
7.15
8.49
40.2
94.2
100 mg QD
(n=9)
11.9
11.6
53.5
93.7
H
200 mg QD
(n=9)
18.2
17.4
80.9
238
PAGE 37View entire presentation